Skip to content

Depression: all studies

Page 288 of 1,036: studies 2,871 to 2,880 of 10,358, newest first. Back to the depression overview

Research

The Impact of Treatments for Depression on the Dynamic Network Structure of Mental States: Two Randomized Controlled Trials.

Scientific Reports April 20, 2017 Evelien Snippe, Wolfgang Viechtbauer, Nicole Geschwind et al.

Evidence is growing that vulnerability to depression may be characterized by strong negative feedback loops between mental states. It is unknown whether such dynamics between mental states can be altered by treatment. This study examined whether treatment with imipramine or treatment with Mindfulness-Based Cognitive Therapy (MBCT) reduces the connectivity within dynamic networks of mental...

Does Intra-ICU Initiation of Guided Mindfulness Meditation Decrease Anxiety and Depression in SAH?: A Unique Methodology for the Neurocritical Care Setting (P5.069)

Neurology April 18, 2017 D. Wheelwright, N. Dangayach, Stephen Griffiths et al.

Objective: We hypothesize that intra-ICU initiation of guided mindfulness meditation is feasible and will help prevent the development of anxiety and depression in good grade SAH patients. Background: Aneurysmal Subarachnoid Hemorrhage (SAH) has a case fatality rate of about 20%. Of all SAH patients, 40% are “good grade” defined as Hunt-Hess 1–2 with normal mental status whereas 60% are poor...

Improvement of mindfulness skills during Mindfulness-Based Cognitive Therapy predicts long-term reductions of neuroticism in persons with recurrent depression in remission.

Journal of Affective Disorders April 15, 2017 Philip Spinhoven, Marloes J. Huijbers, Johan Ormel et al.

This study examined whether changes in mindfulness skills following Mindfulness-based Cognitive Therapy (MBCT) are predictive of long-term changes in personality traits. Using data from the MOMENT study, we included 278 participants with recurrent depression in remission allocated to Mindfulness-Based Cognitive Therapy (MBCT). Mindfulness skills were measured with the FFMQ at baseline, after...

DOI: 10.1016/j.jad.2017.02.011 (opens in new tab) Full text (opens in new tab) Mindfulness-based cognitive therapy Recurrent depression Remission

Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression

Molecular Psychiatry April 11, 2017 Irina Esterlis, Nicole DellaGioia, Robert H Pietrzak et al.

The mechanisms of action of the rapid antidepressant effects of ketamine, an N-methyl-D-aspartate glutamate receptor antagonist, have not been fully elucidated. This study examined the effects of ketamine on ligand binding to a metabotropic glutamatergic receptor (mGluR5) in individuals with major depressive disorder (MDD) and healthy controls. Thirteen healthy and 13 MDD nonsmokers...

Commentary: A Breathing-Based Meditation Intervention for Patients with Major Depressive Disorder Following Inadequate Response to Antidepressants: A Randomized Pilot Study

Frontiers in Medicine April 6, 2017 Skye A. McKennon, S. E. Levitt, G. Bulaj

Citation: McKennon S, Levitt SE and Bulaj G (2017) Commentary: A BreathingBased Meditation Intervention for Patients with Major Depressive Disorder Following Inadequate Response to Antidepressants: A Randomized Pilot Study. Front. Med. 4:37. doi: 10.3389/fmed.2017.00037 Commentary: a Breathing-Based meditation Intervention for Patients with major Depressive Disorder Following Inadequate...

Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight.

The Lancet Psychiatry April 5, 2017 Ilina Singh, Celia J. A. Morgan, Valerie H. Curran et al. 158 citations

We present a review and analysis of the ethical considerations in off-label ketamine use for severe, treatment-resistant depression. The analysis of ethical considerations is contextualised in an overview of the evidence for ketamine use in depression, and a review of the drug's safety profile. We find that, based on current evidence, ketamine use for severe, treatment-resistant depression does...

DOI: 10.1016/s2215-0366(17)30102-5 (opens in new tab) Ketamine treatment ketamine Powerful intervention Fast-acting antidepressant effects Depression treatment depression +9

Accessibility and implementation in the UK NHS services of an effective depression relapse prevention programme: learning from mindfulness-based cognitive therapy through a mixed-methods study

April 3, 2017 J. Rycroft-Malone, Felix Gradinger, Heledd Owen Griffiths et al.

Background: Depression affects as many as one in five people in their lifetime and often runs a recurrent lifetime course. Mindfulness-based cognitive therapy (MBCT) is an effective psychosocial approach that aims to help people at risk of depressive relapse to learn skills to stay well. However, there is an ‘implementation cliff’: access to those who could benefit from MBCT is variable and...

Ketamine and electroconvulsive therapy pairing in depression and mood disorders

April 3, 2017 S. Kose, M. Çetin

Although a number of medications are available for treatment of depressive disorders, one of the major limitations of all present antidepressants is delayed onset of action [1]. In addition, despite recent advances in the pharmacological and non-pharmacological treatment of major depressive disorder, almost one third of patients fail to respond to any treatments [2]. In recent years, one of the...

Reducing anxiety, geriatric depression and worry in a sample of older adults through a mindfulness training program

April 1, 2017 C. Franco, Alberto Amutio, Israel Mañas et al.

This study aimed to analyze the effects of a mindfulness training program on anxiety, worry, and geriatric depression in a sample of older adults. A randomized controlled trial with pretest-posttest measurements was used on an experimental group (n = 42) and a control group (waiting list; n = 45). Participants in the experimental group completed the Short Cognitive Examination, the Penn State...

Clinical predictors of antidepressant response to ketamine in unipolar treatment-resistant depression

European Psychiatry April 1, 2017 L.C. Del Sant, E. Magalhães, Ana C. Lucchese et al.

Introduction: The non-competitive N-methyl-d-aspartate glutamate receptor antagonist ketamine has been shown to have rapid antidepressant effects in treatment-resistant depression (TRD). However, only a few studies have investigated which clinical characteristics predict a response to ketamine. Objectives: To assess sociodemographic variables and clinical markers that predict response to...